AUROMOX
Endophthalmtis
with intra
cameral

Presenting Aurolab Moxifloxacin - Auromox, the advanced fourth-generation fluoroquinolone anti-bacterial agent against a broad spectrum of Gram-positive and Gram-negative ocular pathogens, atypical microorganisms and anaerobes.

• Auromox (Moxifloxacin hydrochloride) administration prevents post- operative anterior chamber reaction.

• Reduces the chance of endophthalmitis by five folds.

• Each of Aurolab's products are made in India, to world-class standards.

• Proved Non-toxic in terms of visual rehabilitation, anterior chamber reaction and corneal edema.

• The MIC level of moxifloxacin is maintained in the anterior chamber for a period of 5 hours making it an effective antibiotic agent for prophylaxis.

• Auromox formulated with ideal pH and Osmolality that is compatible with the human anterior chamber fluid.

• No stromal edema and no drug related adverse effects.

Scientific Studies:

Endophthalmitis reduction with intracameral moxifloxacin in eyes with and without surgical complications: Results from 2 million consecutive cataract surgeries

All cataract surgeries (2 062 643) performed during the 8-year period from 2011 to 2018 at the 10 regional Aravind Eye Hospitals were included in the analysis. With CMP, the overall POE rate declined from 692 (0.07%) of 993 009 eyes to 185 (0.02%) of 1 069 634 eyes (P < 0.001) This was independently significant for phacoemulsification and for M-SICS (P < 0.001) The overall PCR rate was 28 352 (062 643 eyes, and it was statistically higher for trainees irrespective of surgical method |( P < 0.001 . Both staff and trainee surgeons had higher PCR rates with phacoemulsification than with M-SICS (P < 0I) Absent ICMP, PCR increased the overall POE rate by more than 7-fold to63 (0.43%) of 14 505 eyes. ICMP reduced the POE rate after PCR to 25 (0.18%) of 13 847 eyes (P Z .002). This ICMP benefit was separately significant for both M-SICS (0.54% vs 0.26%, PZ.01) and phacoemulsification (0.29% vs 0.06%, PZ.005). The POE rate was especially high after secondary IOL implantation (0.90% without ICMP vs 0.34% with ICMP, PZ 10).axis antibiotic.

AAO Study:

Endophthalmitis reduction with intracameral moxifloxacin prophyiaxis

Overall, 302 815 eyes did not receive IC moxifloxacin and 314 638 eyes did, and there was a significant decline in the endophthalmitis rate, from 0.07% (214/302 815) to 0.02% (64/314 638) (P < 0.001) , with moxifloxacin. For the 194 252 phacoemulsification eyes, the endophthalmitis rate was 0.07% (75/104 894) without IC moxifloxacin prophylaxis, compared with 0.01% (11/89 358) with moxifloxacin (P < 0.001) . For the 414 657 M-SICS eyes, the endophthalmitis rate was 0.07% (135/192 149) without IC moxifloxacin prophylaxis, compared with 0.02% (52/222 508) with moxifloxacin P < 0.001 ). Approximately half of the 8479 eyes that had PCR received IC moxifloxacin, and half did not. Without IC moxifloxacin, PCR increased the endophthalmitis rate early 7-fold to 0.48% (20/4186); IC moxifloxacin reduced the endophthalmitis rate with PCR to 0.21% (9/4293) (P1% 0.034). No adverse events were due to IC moxifloxacin.